Market Overview
In a day marked by geopolitical tensions and economic uncertainties, Wall Street navigated a turbulent session, leaving investors to ponder the implications for tomorrow. The market's volatility was fueled by a confluence of factors, including escalating US-Iran tensions, persistent inflationary pressures, and sector-specific dynamics that underscored the intricate interplay between macroeconomic forces and corporate developments. The specter of inflation loomed large, reigniting fears of aggressive rate hikes by the Federal Reserve. The consumer price index, excluding food and energy, rose by 0.3% from the previous month, surpassing expectations for the third consecutive month. This persistent inflationary trend, exacerbated by the US-Israel conflict with Iran, ongoing trade tensions, and the burgeoning AI data center boom, has set the stage for a potentially more hawkish stance from the Fed at its upcoming December policy meeting. Investors, already bracing for a quarter-point rate increase, now face the possibility of a more substantial hike, sending ripples through the bond market as yields surged. Amidst this macroeconomic backdrop, sector-specific rotations painted a vivid picture of market sentiment. The airline industry, grappling with soaring energy prices driven by the Iran conflict, faced a challenging outlook as fuel costs are projected to remain elevated well into the new year. This has cast a shadow over the sector's recovery prospects, even as geopolitical tensions begin to ease. In contrast, the semiconductor sector experienced a mixed performance. Nvidia, embroiled in a probe concerning its CEO's alleged affair with a Chinese spy, saw its stock plummet, reflecting investor concerns over leadership stability and future prospects. Meanwhile, CoreWeave delivered a robust earnings report, easing market anxieties and highlighting the resilience of certain tech sub-sectors amidst broader uncertainties. The energy sector, too, felt the impact of geopolitical developments. As the Iran war's fallout continued to reverberate, energy prices remained stubbornly high, influencing broader market dynamics and investor sentiment. This has underscored the sector's sensitivity to geopolitical risks, with implications for global supply chains and economic growth. Corporate developments further colored the market landscape. International Business Machines (IBM) announced the cessation of immigration sponsorship for some roles in its consulting division, a move reflecting broader immigration policy shifts and their impact on talent acquisition strategies. This decision highlights the challenges faced by tech giants in navigating regulatory environments while striving to maintain competitive edges. As the market closed, the interplay between these macroeconomic and micro-level factors left investors with a complex tapestry of risks and opportunities. The looming Fed decision, coupled with ongoing geopolitical tensions and sector-specific dynamics, will undoubtedly shape market trajectories in the days ahead. Investors, therefore, must remain vigilant, balancing short-term volatility with long-term strategic considerations in an increasingly uncertain global landscape.
In a volatile after-hours session, the US stock market was significantly influenced by geopolitical tensions and persistent inflationary pressures, which were reflected in the movements of sector ETFs. The energy sector ETF (XLE) saw a notable increase of 0.4359%, driven by sustained high energy prices amid the US-Iran conflict. This uptick underscores the sector's sensitivity to geopolitical risks, which are likely to continue influencing energy prices and investor sentiment in the near term. Conversely, the technology sector, represented by XLK, experienced a sharp decline of 1.1529%. This drop can be attributed to Nvidia's leadership turmoil and broader concerns over regulatory and geopolitical challenges facing tech companies. Despite CoreWeave's positive earnings report, the sector remains under pressure, suggesting that tech investors are cautious about the potential for increased regulatory scrutiny and geopolitical instability. The financial sector ETF (XLF) also saw a rise of 0.5173%, likely buoyed by the prospect of more aggressive rate hikes by the Federal Reserve in response to persistent inflation. This sentiment is reflected in the bond market's reaction, with yields surging as investors anticipate a more hawkish stance from the Fed. The financial sector's performance indicates that investors are positioning for a rate hike environment, which could continue to support financial stocks in the coming sessions. Overall, the interplay between macroeconomic forces and sector-specific dynamics has created a complex landscape for investors. While energy and financials have benefited from current conditions, technology faces headwinds that may persist. Investors will need to navigate these uncertainties, balancing short-term volatility with long-term strategic considerations as they assess the evolving market environment.
Market Insights
U.S. equities edged higher in subdued trading, with the advance largely driven by tech megacaps, while broader market participation waned. More than two-thirds of advancing stocks did so on below-average volume, indicating that institutional desks remained largely on the sidelines despite the green tape. This divergence in volume suggests tape fragility under light conditions, raising concerns about the sustainability of the rally. Mega-caps, with an average return of 0.52% and a beta of 1.16, underperformed relative to the broader market, highlighting a disconnect between large-cap performance and overall market trends. Beta analysis revealed that low beta stocks outperformed the market with a 0.76% average return, while high beta stocks lagged with a -0.80% average return. High-beta bellwethers carried the market, overshadowing defensive cohorts as the median stock achieved only modest gains. Despite superficially favorable market breadth for bulls, the lack of volume confirmation leaves the market vulnerable to sharp reversals if macroeconomic headlines trigger sudden selling. This fragility underscores the need for caution as the market navigates uncertain terrain.
Next Day Option Data
QQQ
SPY
IWM
6-K/8-K Form Update
SPRO
Spero Therapeutics, Inc. announced a board reshuffle in its recent Form 8-K filing. Patrick Vink, M.D., resigned from the Board, effective November 10, 2026, and William Ho, M.D., Ph.D., was appointed as a Class II director to fill the vacancy. Dr. Ho, with over 20 years in clinical development and experience at RAPT Therapeutics, brings expertise in immunotherapy and novel therapeutics to Spero's leadership team.
AHT-PI
Ashford Hospitality Trust, Inc. reported a 7.3% increase in third-quarter 2026 RevPAR to $140.8, driven by a 6.1% rise in ADR and a 1.2% increase in occupancy. Net income attributable to common stockholders was $2.5 million or $0.12 per diluted share, compared to a net loss of $(69.0) million in the prior-year quarter. Adjusted EBITDA was $34.9 million, and year-to-date AFFO per diluted share improved to $0.44 from $(3.13) a year ago. Total debt decreased 26.4% to $1.9 billion, and interest expense fell 15.9% to $47.4 million. The company also announced hotel sales totaling $145.8 million in gross proceeds and refinanced the Highland loan pool at a lower spread.
VIVK
Vivakor, Inc. entered into a Consulting Agreement with former COO Les Patterson, agreeing to issue $20,000 in shares per month for logistical services. Concurrently, J.J. Astor & Co. converted $844,622 of a junior secured convertible promissory note into 4,351,341 shares of Vivakor's common stock, exempt under Section 4(a)(2) of the Securities Act as J.J. Astor is an accredited investor.
RLYB
Rallybio Corporation announced a one-for-two reverse stock split of its common stock in connection with its proposed merger with Avenzo Therapeutics, Inc. The split, effective at 12:01 a.m. Eastern Time on November 20, 2026, will reduce outstanding shares from approximately 5.6 million to 2.8 million, prior to the merger's completion. Following the merger and Nasdaq approvals, Rallybio plans to rebrand as Avenzo Therapeutics, Inc., trading under the symbol "AVZO."
CRMD
CorMedix Inc. agreed to acquire substantially all of the assets of Heron Therapeutics, Inc. for approximately $1.2 billion, subject to customary closing adjustments and conditions. The transaction, expected to close in the first quarter of 2027, is contingent on regulatory approvals and aims to enhance earnings through synergies and the integration of Heron's FDA-approved brands. CorMedix will issue common stock in a private placement to Heron, relying on an exemption from the Securities Act registration requirements.
GGG
Graco Inc. has entered into an accelerated share repurchase agreement with Bank of America, N.A., to repurchase $600 million of its common stock, representing approximately 5% of its outstanding shares. The transaction, funded through cash and borrowings, is expected to initially retire about 6.9 million shares, with the final number determined at settlement. Completion is anticipated in March 2027, adding to the approximately 8 million shares remaining under the company's existing repurchase authorization.
CPIX
Cumberland Pharmaceuticals Inc. completed a $100 million Strategic Transaction with Apotex Health, integrating its commercial brands into Apotex's U.S. business, thereby strengthening its balance sheet. The company plans to submit a New Drug Application (NDA) for ifetroban, a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy, following a rolling review request granted by the FDA. Cumberland reported a net income of $77.8 million for the quarter, with revenues and expenses from the transaction classified as discontinued operations.
LEU
Centrus Energy appointed Kevin Graney to its Board of Directors on November 4, 2026. Graney, with nearly three decades of experience in nuclear technology, advanced manufacturing, and national security, will join immediately. Prior roles include President of Electric Boat and National Steel and Shipbuilding Company, where he oversaw operations for U.S. Navy submarines. Graney aims to expand U.S. uranium enrichment capacity, emphasizing the importance of industrial capabilities critical to national security.
ZDPY
Zoned Properties, Inc. declared a special cash dividend of $0.41 per share, payable on November 20, 2026, to common stockholders of record as of November 11, 2026. The dividend, representing over 25% of the share price, will result in shares trading with "due bills" from November 11 to November 20, 2026. The company has divested all cannabis-related operations and anticipates settling remaining debts and agreements, with plans for a reverse merger or similar transaction, though completion is not guaranteed.
LVO
LiveOne, Inc. reported preliminary financial results for the first half of Fiscal 2027, revealing revenue of $37.3 million and record Audio Adjusted EBITDA of $7.8 million, up 619% from the previous year. The company revised its Fiscal 2027 guidance to $70-$75 million in revenue and $10 million+ in Adjusted EBITDA, anticipating a significant partnership launch. Additionally, LiveOne extinguished $25 million in debt, reducing its senior debt balance to $9 million since February 2026.
DLPN
Dolphin Entertainment, Inc. reported record revenue of $16.0 million for the third quarter ended September 30, 2026, marking an 8.3% year-over-year increase. The company posted net income of $0.2 million or $0.02 per share, with adjusted EBITDA of $1.6 million or $0.12 per share, reflecting a 42.9% increase year-over-year. Dolphin anticipates four ventures in 2027, highlighting improvements in profitability, cash flow, and operational efficiency, while maintaining strong free cash flow.
ORC
Orchid Island Capital, Inc. declared a monthly cash dividend of $0.10 per share, payable on December 31, 2026, to shareholders of record on November 30, 2026, with an ex-dividend date of November 30, 2026. The estimated book value per share increased by approximately 8% to 9% from September 30, 2026, to $6.52 to $6.54 as of November 6, 2026. The company's RMBS portfolio includes 192,992,160 shares of common stock, with a weighted average coupon of 5.55% and maturity of 23 months, while regulatory requirements mandate distributing at least 90% of its REIT taxable income.
HYLN
Hyliion Holdings Corp. reported third-quarter 2026 financial results, showing revenue of $7.5 million, exceeding expectations due to progress on the 800-kW KARNO Power Module and additional funding. The company anticipates approximately $8 million in additional military contract awards before year-end, reaching the high end of its $40 million to $50 million objective. Hyliion's net loss improved by 17% to $11.1 million, with nine-month revenue reaching $15.2 million, up from $2.8 million in 2025.
INM
Mentari Therapeutics, Inc. completed a merger and reorganization with Indigo Merger Sub Corp. and Indigo Merger Sub II, LLC, resulting in its redomiciliation from British Columbia, Canada, to Nevada. Prior to the merger, the company underwent a reverse stock split and rebranded from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc., with adjustments to its articles and preferred shares. Post-merger, InMed common shares were consolidated at a 1:10 ratio, and securityholders of both companies received shares in the combined entity, with Mentari securityholders owning approximately 99.0% and InMed securityholders owning about 1.0% of the combined company on a fully diluted basis.
KRMD
Koru Medical Systems, Inc. reported third-quarter 2026 results, showing net revenues grew 11% to $11.6 million, with net income improving to $0.2 million from a prior loss of $0.8 million. The company expanded its international presence by signing sales and distribution agreements in Europe and Africa, revising full-year revenue guidance to $48.0 - $48.5 million, indicating 17% - 18% growth. Gross margin increased to 65.2%, driven by lower manufacturing costs and higher selling prices.
TRON
Tron Inc. reported robust financial results for the nine months ended September 30, 2026, with net income surging 203% year-over-year to $39.4 million and total assets growing 30% to $275.2 million. The company's digital asset investments increased to $257.8 million, while staking-related income more than quadrupled to $9.5 million. Tron Inc. also achieved a strategic milestone by being elected as one of the TRON Network's 27 Super Representatives, enhancing its participation in network infrastructure and rewards.
INBS
Intelligent Bio Solutions Inc. reported record fiscal first quarter 2027 revenue of $1.39 million, marking the sixth consecutive quarter of year-over-year growth, with revenue up 25% year-over-year and 21% sequentially. Higher-margin cartridge sales, representing 61% of total revenue, grew 32% year-over-year and 35% sequentially, while gross profit margin expanded to 54.5%. The company submitted its FDA 510(k) premarket notification, a key step toward U.S. market entry, and completed its clinical program for the Intelligent Fingerprinting Drug Screening System, demonstrating high accuracy, sensitivity, and specificity.
ELV
Elevance Health, Inc. announced its earnings guidance for full year 2026, targeting at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items, and adjusted shareholders' earnings of at least $29.00 per diluted share. The company reaffirmed its benefit expense ratio guidance of 90.2% plus or minus 50 basis points, while acknowledging potential risks and uncertainties that could impact future operations and performance.
NRGV
Energy Vault Holdings, Inc. reaffirmed its full-year 2026 revenue guidance of $290-$310 million, supported by expected Q4 project deliveries. The company's contract backlog surged to $2.3 billion, up 147% year-over-year, while total cash increased to $236 million, up 281% year-over-year. Energy Vault completed a portfolio acquisition from Goshe Energy Storage, securing a $40 million credit facility from S2G Investments and received grid interconnection approval for the Stoney Creek project in Australia, setting the stage for accelerated construction.
AIRI
Air Industries Group extended the maturity date of its revolving credit and term loans to April 30, 2027, by amending its Loan and Security Agreement with its primary lender. The company paid a $50,000 amendment fee and agreed to an additional $50,000 fee upon maturity. Concurrently, holders of convertible and nonconvertible subordinated notes extended their maturity to May 1, 2027, with terms adjusting if a merger with Tenax Aerospace Acquisition, LLC, and Transitory Air Sub LLC does not occur by November 30, 2026.
BSIN
Big Sky Industrial Inc. announced its financial results for the three and nine months ended September 30, 2026, highlighting progress at its Big Sky Carbon Hub project in Montana, where phase 1 processing facility fabrication has commenced. The company underscored the strategic importance of its helium supply, designated as a critical material by the Department of Energy, and is in discussions for a new credit facility to enhance financial flexibility. Big Sky Industrial is targeting first production in spring 2027, with ongoing 45Q monetization discussions and anticipates EPA approval of its Big Rose MRV plan within a 12-month timeframe.
AROC
Archrock, Inc. agreed to merge its subsidiary, Archrock Services, L.P., with HiVolt Energy Holdings, LLC, with HiVolt continuing as the surviving entity. The $415 million transaction involves converting HiVolt's Class A and Class B units into cash, subject to adjustments, and includes an incentive plan for HiVolt employees worth up to $35 million over fiscal years 2027-2029. The merger, expected to close in Q1 2027, is contingent on regulatory approvals and key employment agreements.
SONO
Sonos, Inc. announced a $150 million common stock repurchase program, following the completion of its prior $150 million repurchase program in fiscal 2026 Q4. The company reported fiscal 2026 results, marking its return to revenue growth with a 7% year-over-year increase to $1,547 million, and significant improvements in GAAP net income and Adjusted EBITDA, which grew 39% year-over-year to $184 million. Sonos returned $165 million to shareholders through share repurchases and highlighted its strong financial performance with a 92% year-over-year increase in Non-GAAP net income to $150 million.
HGTY
Hagerty, Inc. announced the commencement of a secondary public offering of 9 million shares of its Class A Common Stock, underwritten by J.P. Morgan and Wells Fargo Securities. The net proceeds will be used to redeem a corresponding number of shares by the Kim Hagerty Revocable Trust. The underwriters have a 30-day option to purchase an additional 1.35 million shares, subject to registration requirements under the Securities Act of 1933.
ATROB
Astronics Corporation reported record operating income of $54.0 million, or 19.9% of sales, on a 28.5% increase in sales to $271.7 million for the third quarter of 2026. The company's adjusted operating income was $51.0 million, or 18.8% of sales, with net income reaching $52.2 million, or $1.08 per diluted share, compared to a net loss of $11.1 million in the prior-year period. Bookings reached $271.1 million, resulting in a book-to-bill ratio of 1.00:1, and backlog stood at $780.0 million at quarter end.
GPRO
GoPro, Inc. faces a delay in filing its quarterly financial report due to challenges in completing financial close procedures and valuing certain financing arrangements. The company identified a material weakness in its internal control over financial reporting related to these arrangements, which remains unremediated. Consequently, GoPro is unable to announce its third-quarter earnings and anticipates a significant decrease in net revenue, gross margin, and operating expenses for the quarter ended September 30, 2026, raising substantial doubt about its ability to continue as a going concern for the next twelve months.
NHPAP
National Healthcare Properties, Inc. completed the acquisition of 24 senior housing operating portfolio communities in November 2026, exceeding 50% significance under Regulation S-X, and filed pro forma financial information in a Current Report on Form 8-K. The company anticipates completing additional acquisitions in the fourth quarter of 2026 or first quarter of 2027, with pro forma financials reflecting these impacts also included in the report. Additionally, it is set to sell its portfolio of 40 outpatient medical facilities for approximately $531 million, with the transaction expected to close in the fourth quarter of 2026, and related pro forma financials have been filed.
SPIR
Spire Global reported a 42% year-over-year revenue increase to $18.0 million for the third quarter of 2026, driven by growth in Space Services data delivery and Hyperspectral Microwave Sensor sounding data sales. The company's net loss was $20.3 million, while adjusted EBITDA improved by 27% to $(8.6) million. Cash flow used in operations decreased by 59% to $5.0 million, and Spire secured a $33.2 million task order from NOAA and a $28 million contract for hyperspectral microwave technology advancement. Full-year revenue is expected between $75 million and $80 million, with adjusted EBITDA between $(32.4) million and $(27.4) million.
NLST
Netlist, Inc. reported a 149% year-over-year increase in net sales to $105.1 million for the third quarter of 2026, driven by $44.9 million in license fee revenue from the Samsung agreement. The company's balance sheet strengthened, with cash, cash equivalents, and restricted cash rising to $327.7 million, primarily due to initial payments from Samsung. Gross margin improved to 65.5%, and net income reached $85.4 million, or $0.22 per diluted share, compared to a net loss of $7.0 million in the same period last year.
NXTC
NextCure, Inc. reported third-quarter 2026 financial results, showing a decrease in cash, cash equivalents, and marketable securities to $8.7 million from $41.8 million as of December 31, 2025, primarily due to $35.2 million in cash used for operations. The company's research and development expenses decreased to $4.5 million from $6.1 million, while general and administrative expenses increased to $4.4 million from $2.8 million, mainly due to higher legal and professional fees related to the proposed merger with Avere Therapeutics. NextCure completed significant restructuring initiatives, resulting in reduced future operating cash requirements, and transitioned the LNCB74 program to LigaChem Biosciences, Inc., with potential future milestone payments and royalties.
IIIN
Insteel Industries Inc. declared a regular quarterly cash dividend of $0.03 per share and a one-time special cash dividend of $1.00 per share, both payable on December 11, 2026, to shareholders of record as of November 27, 2026. The special dividend reflects the company's confidence in its financial position and long-term outlook, while providing a meaningful return to shareholders. Insteel, the nation's largest manufacturer of steel wire reinforcing products, operates ten manufacturing facilities in the United States.
GENK
GEN Restaurant Group, Inc. reported a 3.3% decrease in third-quarter 2026 revenue to $48.7 million, with restaurant revenue falling 12.7% to $44.0 million due to a 9.2% decline in comparable sales and fewer restaurants in the base. The company signed a binding letter of intent with Chubby Group for the sale of 47 U.S. GEN Korean BBQ restaurants, aiming to reduce operating lease liabilities and eliminate outstanding debt. GEN anticipates reaching a CPG revenue run rate of $40 million per year and positive consolidated net income by the end of 2027, following a 15% reduction in corporate overhead.
AAON
AAON, Inc. declared a quarterly cash dividend of $0.10 per share, payable on December 17, 2026, to stockholders of record as of November 25, 2026. The company disclosed a material weakness in the effectiveness of its internal controls over financial reporting, necessitating timely remediation. This announcement highlights both a commitment to shareholder returns and a focus on strengthening financial governance.
LPTH
LightPath Technologies, Inc. reported a 38% revenue increase to $20.8 million in the fiscal 2027 first quarter, driven by growth in assemblies and modules revenue, which rose to 51% of total revenue. Gross profit surged 92% to $41.4% of revenue, benefiting from a significant margin expansion due to a higher revenue mix. The company secured over $30 million in follow-on C-UAS orders from July to October 2026 and completed the sale of its China subsidiary.
STIM
Neuronetics, Inc. amended its credit agreement with Perceptive Credit Holdings IV, LP, and other lenders, modifying certain revenue covenants. The amendment, contingent on an optional prepayment of $15 million plus accrued interest and fees, will automatically terminate if conditions are unmet by November 30, 2026. Additionally, the agreement adjusts the early prepayment fee and introduces new definitions, representations, and warranties.
BRCB
Black Rock Coffee Bar, Inc. reported third-quarter 2026 results, showcasing a 29.7% year-over-year revenue increase to $66.8 million, with same-store sales growth of 5.8%. The company opened 11 new stores, surpassing its development plan and raising the full-year target to 40 new openings. Income from operations improved to $2.8 million from a prior loss of $6.4 million, with a store-level profit margin of 28.9%. Selling, general, and administrative expenses decreased to 15.5% of total revenue, and adjusted EBITDA grew 22.1% to $8.5 million. The company reaffirmed its full-year guidance, anticipating total revenue between $255 million and $257 million, adjusted EBITDA of $34 million to $35 million, and capital expenditures of $47 million to $48 million.
OPFI-WT
OppFi Inc. announced a proposed acquisition of BNCCORP, Inc., subject to conditions and regulatory approvals, and disclosed a change in its Chief Financial Officer, appointing Pamela D. Johnson. The company also confirmed its compliance with Nasdaq listing standards and its status as not being an emerging growth company under relevant securities rules. OppFi plans to update its investor presentation to reflect future developments.
MBRX
Moleculin Biotech, Inc. unveiled preclinical data demonstrating that its lead drug candidate, Annamycin, in combination with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The combination resulted in higher pancreatic tissue exposure and increased infiltration of CD8+ and CD4+ T cells compared to doxorubicin, indicating potential for immunotherapy strategies in treating pancreatic cancer.
FLY
Firefly Aerospace Inc. reported a 259% revenue increase to $110.7 million in the third quarter of 2026, with a record backlog of $1.7 billion. The company expanded its spacecraft cleanroom, secured European launch contracts, and won key contracts including a $981 million Space Force IDIQ contract. Firefly also partnered with Starcloud for lunar data center capabilities and anticipates full-year revenue between $440 million and $450 million.
SLAB
Silicon Laboratories Inc. reported fiscal quarter revenue of $251 million, up 22% year-over-year, driven by growth across various segments. The Industrial & Commercial segment increased 20% to $141 million, while Home & Life surged 24% to $110 million. Medical revenue reached a new quarterly record, up 48% sequentially and over 300% year-over-year. GAAP diluted earnings per share improved to $0.26 from a year-ago loss of $0.30, and Non-GAAP diluted earnings per share reached $1.05, a 228% increase. The company has suspended forward-looking guidance due to the pending acquisition by Texas Instruments.
PACB
Pacific Biosciences of California, Inc. agreed to sell up to $100 million in aggregate gross proceeds of its common stock through an at-the-market equity offering program, with Allen & Company LLC acting as the sales agent. The agreement allows Pacific Biosciences to set parameters for the sale, including the number or dollar amount of shares, time period, daily sales limitations, and minimum price. Allen & Company will use commercially reasonable efforts to conduct sales, with Pacific Biosciences having no obligation to sell any shares and the option to suspend offers.
QTIWW
QT Imaging Holdings, Inc. reported robust third-quarter financial results for 2026, with revenue surging 75% year-over-year to $7.3 million, totaling $21.3 million for the first nine months. The company secured a major Medicare hospital outpatient payment for diagnostic QTscan examinations, effective January 1, 2027, enhancing its expansion potential into U.S. hospitals and health systems. QT Imaging doubled its manufacturing capacity with a move to a new 22,000-square-foot facility in Petaluma, California, and revised its full-year 2026 revenue guidance to approximately $34 million due to shipment delays from the Middle East conflict.
PRME
Prime Medicine, Inc. is advancing its Prime Editing technology with ongoing clinical trials targeting Wilson disease and Alpha-1 Antitrypsin Deficiency. The company has initiated Phase 1/2 trials for PM577a and PM647, with data expected in 2027, and is leveraging its platform's modularity for future liver programs. Prime Medicine holds extensive intellectual property for Prime Editing and is developing a proprietary LNP-formulated Prime Editor for various indications, including Cystic Fibrosis and chronic granulomatous disease. Strategic partnerships, such as with Bristol Myers Squibb, aim to expand reach and commercialize ex vivo T cell products in immunology and oncology.
QMLS
QumulusAI, Inc. reported a 376% revenue increase to $14.8 million in the third quarter of 2026, with compute power revenue accounting for approximately 96% of the total. The company's cumulative signed customer contract value reached $528.7 million, bolstered by $240.9 million in new three-year agreements covering over 2,000 NVIDIA Blackwell B300 GPUs. Despite an operating loss widening to $41.6 million, adjusted EBITDA turned positive at $3.7 million, marking the first positive quarter.
CRWV
CoreWeave, Inc. reported robust financial results for the third quarter ended September 30, 2026, with revenue surging by over $1 billion sequentially and adjusted operating margins reaching double digits ahead of schedule. The company's revenue backlog stood at approximately $132.5 billion, bolstered by customer wins across AI labs, hyperscalers, and enterprises, including partnerships with Canva and Wayve. CoreWeave expanded its infrastructure capacity significantly, adding over 200 MWs of active power to reach over 1.7 GW, and raised approximately $4.2 billion through an upsized offering of convertible senior notes.
LMRI
Lumexa Imaging Holdings, Inc. reported third-quarter 2026 results, showing consolidated revenue growth of 5.0% to $272.0 million and system-wide growth of 7.7%. The company achieved a net income of $7.2 million, up from a net loss of $3.5 million in the prior year quarter, with Adjusted EBITDA of $62.6 million and an Adjusted EBITDA margin of 23.0%. Lumexa Imaging reiterated its full-year revenue guidance of $1.045 billion to $1.097 billion and raised its Adjusted EPS guidance to $0.86 to $0.90 per share, while announcing plans to open three new de novo centers in 2026.
ATEX
Anterix Inc. reported its second quarter fiscal year 2027 results, with $33.1 million in contracted proceeds outstanding and $9.6 million expected to be received during the fiscal year. The company recorded a $6.1 million gain from exchanging narrowband for broadband licenses in six counties and invested $5.4 million in spectrum clearing costs. As of September 30, 2026, Anterix had no debt, $107.5 million in cash and cash equivalents, and $3.2 million in restricted cash, with an authorized share repurchase program of up to $250 million remaining available.
CARL
Carlsmed, Inc. reported a 65% year-over-year revenue increase to $21.6 million for the quarter ended September 30, 2026, driven by strategic execution. The company raised its full-year 2026 revenue guidance to $78 million to $80 million, representing over 56% growth at the midpoint, and announced leadership changes with Jeff Bertolini as Chief Operating Officer, Rich Heppenstall as Chief Financial Officer, and Tony Jarc, Ph.D., as Chief Product and AI Officer. Additionally, Carlsmed secured new inpatient CMS reimbursement for its aprevo® lumbar spine fusion procedure and expanded its personalized surgery platform with the launch of the aprevo® Lumbar Bi-lateral Posterior System.
MCHX
Marchex, Inc. appointed Travis Fairchild as President, effective November 9, 2026, following his tenure as CEO of Archenia, Inc., which Marchex acquired in July 2026. Fairchild, with 18 years of experience at Marchex, was granted 800,000 restricted stock units (RSUs) with staggered vesting over three and five years. Troy Hartless will continue as Chief Revenue Officer, focusing on new opportunities and sales channels.
ACHV
Achieve Life Sciences, Inc. reported a cash increase to $201.5 million as of September 30, 2026, driven by proceeds from exercised warrants. The company showcased promising quit rates in its ORCA-OL trial at the CHEST 2026 Annual Meeting and completed commercial-scale stability batches for its U.S. drug product manufacturing. Transitioning to AchieveRx, The Quit Company, with the Nasdaq ticker "QUIT," the firm anticipates potential FDA approval by the second quarter of 2027, with a subsequent U.S. commercial launch.
WKSP
Worksport Ltd. reported a record Q3 2026 net sales of $7.2 million, up 44.2% year-over-year, while net loss narrowed 27% to $3.6 million. Operating expenses fell 11.7% year-over-year, and inventory declined 20.6% to approximately $9.6 million. The company signed a non-binding term sheet to acquire a business selling a patented truck-bed accessory, subject to due diligence and closing conditions.
AVD
American Vanguard Corporation reported unaudited financial results for the third quarter and nine-months ended September 30, 2026, with net sales decreasing to $108 million from $119 million, and gross profit margin declining to 24% from 29%. The company's operating loss widened to $8.0 million, and net loss grew to $17.7 million, while adjusted EBITDA was revised downward to $36 million to $40 million on expected sales of $500 million to $530 million. American Vanguard expanded its product portfolio by acquiring four U.S. brands and registrations from Syngenta and entering into a distribution agreement with Sipcam Agro.
XCUR
Exicure, Inc. and its subsidiary GPCR Therapeutics USA Inc. agreed to sell assets and rights related to the GPC-100 program to GPCRT Inc. The transaction, valued at approximately US$4.8 million, involves the transfer of intellectual property, clinical data, and other assets, with payment structured in three cash installments. The deal, pending customary closing conditions and regulatory approvals, will see the Purchaser assume specified liabilities and obligations, while certain costs remain reimbursable under a separate arrangement.
STLD
Steel Dynamics, Inc. authorized an additional $3.0 billion share repurchase program, bringing the total to $4.5 billion, effective immediately. The company also declared a quarterly cash dividend of $0.53 per common share, payable on January 8, 2027. Since 2017, Steel Dynamics has repurchased $8.2 billion of its common stock, representing 45% of its outstanding shares, and has paid $2.2 billion in cash dividends through September 30, 2026.
JUSHF
Jushi Holdings Inc. updated its investor presentation, revealing an adjusted EBITDA of $52 million and third-quarter revenue of approximately $277 million for 2026. The company announced a three-year, 12.5% coupon term loan with interest-only payments and disclosed key executive appointments, including a president, chief revenue officer, and corporate secretary. As an emerging growth company, Jushi Holdings Inc. has not elected to use the extended transition period for new financial accounting standards compliance.
SVV
Savers Value Village, Inc. (NYSE: SVV) unveiled its ThriftIQ pricing platform, Autotagger, and integrated Image Capture technologies during an Innovation Day on November 10, 2026. These initiatives are central to the company's strategy to expand its Adjusted EBITDA margin by 50 to 100 basis points annually over the next three years. ThriftIQ, operational in 108 stores, has priced over 40 million items, contributing to faster gross profit growth and higher sales yields, while Autotagger and image capture solutions are projected to save over $10 million annually upon full implementation.
GUER
Guerrilla RF, Inc. executed a recapitalization transaction, converting 22,000 shares of Series A convertible preferred stock into 7,213,115 shares of common stock. The company reclassified warrants from debt to equity, affecting 2,895,709 shares of common stock, with fair value adjustments recognized in earnings as of October 30, 2026. This strategic move aims to streamline the company's capital structure and enhance shareholder value.
SPAI
Safe Pro Group Inc. secured a $2.5 million milestone U.S. Government Prime Contract to enhance the Army's Abrams Tanks with its patented super intelligence (SI)-powered threat detection software on Anduril Industries' Ghost-X drone platform. The contract, awarded under a Commercial Solutions Opening for Ground Threat Detection through Aerial Reconnaissance, enables real-time identification and geolocation of over 150 types of explosive threats. Safe Pro's technology processes live video onboard drones, streaming threat data directly into U.S. Army networks, optimizing mission-ready intelligence, surveillance, and reconnaissance capabilities.
MANE
Veradermics, Incorporated reported third-quarter 2026 financial results, highlighting significant clinical progress with positive topline results from Phase 3 Study '304' and Phase 2/3 Study '302' in male pattern hair loss, and Phase 2 Study '207' in female pattern hair loss. The company completed enrollment in Phase 2/3 Study '306' for VDPHL01, with data expected in early 2027. Veradermics maintains a cash position of $798.4 million as of September 30, 2026, projected to support operations through 2030.
COSM
Cosmos Health Inc. announced a reverse stock split amendment to its Articles of Incorporation, effective November 12, 2026, at 4 PM local time. The Board of Directors approved a 1-for-20 reverse stock split ratio, maintaining the company's authorized shares of common stock at 1.5 billion and preferred stock at 300 million shares. The amendment, filed as Exhibit 3.1, will reclassify and convert 20 shares of Old Common Stock into one share of New Common Stock, with fractional share interests rounded up to whole shares.
RXT
Rackspace Technology, Inc. secured compliance through a private placement, issuing 18,181,816 shares to Voss Capital, LP, for approximately $50 million on November 6, 2026. Additionally, on November 9, 2026, the company issued 5,818,181 shares to other purchasers for about $16 million. The total issuance of 24 million shares, valued at $66 million, was conducted under Section 4(a)(2) of the Securities Act, targeting accredited investors, and the shares are classified as restricted securities.
FLEX
Flex Ltd. announced plans to spin off its Cloud and Power Infrastructure segment into an independent publicly-traded company, Axiom Solutions International, Inc., during an Innovation Day event in Austin, Texas. The company intends to sell 200,000 shares of Axiom's Series A Convertible Preferred Stock in a private placement, subject to certain conditions. Flex expects to complete the spin-off and the Preferred Investment within the anticipated timeframe, though various risks and uncertainties could affect the outcomes.
MXCT
MaxCyte, Inc. agreed to acquire Akron BioProducts LLC in a deal valued at $125 million, comprising $105 million in cash, 20.6 million shares of common stock, and $20 million in deferred payments. The transaction, expected to close before year-end 2026, is contingent on customary closing conditions, including Nasdaq listing approval for the stock consideration. The deal is not subject to financing conditions or shareholder approval, with the stock consideration exempt from registration under Section 4(a)(2) of the Securities Act.
CINGW
Cingulate Inc. is addressing the FDA's Complete Response Letter regarding its lead asset, CTx-1301, for ADHD treatment, with plans to resubmit the New Drug Application promptly. Chairman and CEO Shane J. Schaffer provided an update on regulatory progress and commercialization strategies in an interview. The company is preparing for a successful product launch, as highlighted in recent presentations at the Indegene Digital Summit.
TLSIW
TriSalus Life Sciences, Inc. reported third-quarter 2026 revenue of $12.9 million, marking an 11.3% year-over-year increase, driven by expanded commercial operations and market penetration. The company revised its 2026 revenue guidance to $46 million to $48 million, indicating growth of 2% to 6% over 2025. Key developments include FDA clearance for TriNav Advance and CMS policies expanding reimbursement for Pressure-Enabled Drug Delivery, with Medicare payment rates for related procedures set to rise significantly in 2027.
JRSH
Jerash Holdings (US), Inc. reported a 19.8% revenue increase to $50.3 million for the fiscal year 2027 second quarter, driven by higher shipments to major U.S. customers. Gross profit surged 45.4% to $9.1 million, with gross margin expanding to 18.2%, supported by efficiency gains and tighter controls. Operating income nearly tripled, and net income rose to $2.2 million, with third-quarter revenue expected to grow 17-22% amid rising transportation costs.
CRMT
America's Car-Mart, Inc. secured compliance with a First Amendment to its Credit and Guaranty Agreement with Silver Point Finance, LLC, and associated lenders. The amendment, effective from its signing until November 12, 2026, provides limited waivers for certain events of default and extends obligations to maintain minimum liquidity and Collateral Coverage Ratios. This adjustment follows the original agreement dated October 30, 2025.
PEPG
PepGen Inc. reported positive third-quarter 2026 financial results, highlighting a 46.5% splicing correction in the Phase 2 FREEDOM2-DM1 trial for myotonic dystrophy type 1, with notable functional improvements. The company remains well-funded with $104.8 million in cash, sufficient to support operations through 2028, and announced full enrollment in the 12.5 mg/kg cohort, with results expected in early 2027. PepGen is addressing a partial clinical hold from the FDA on the FREEDOM2 study due to nonclinical findings in mice, while advancing nonclinical studies and engaging in a CDRP program to align on manufacturing strategies.
ASTS
Rakuten Group, Inc. and AST SpaceMobile, Inc. established Rakuten AST, Inc., a joint venture to build a direct-to-device communications network in Japan using low Earth orbit satellites. The Ministry of Internal Affairs and Communications selected their proposal for the "J-LEO: Japan Low Earth Orbit Satellite Communications Project," with Rakuten AST expected to receive up to 148 billion yen in support over three years. The venture plans to deploy satellites by March 2029, aiming to enhance Japan's communications infrastructure, especially during emergencies.
MCFT
MasterCraft Boat Holdings, Inc. reported a robust financial performance for the first three months of its transition period, ending October 4, 2026, with consolidated net sales reaching $154.1 million, marking a 123.4% year-over-year increase. The surge was primarily driven by $59.3 million in incremental net sales from the Marine Products Transaction. Adjusted EBITDA rose 137.1% to $20.1 million, while adjusted net income climbed to $12.2 million, or $0.50 per diluted share, compared to $4.7 million, or $0.29 per diluted share, in the prior-year period. The company projects consolidated net sales for the transition period to be between $293 million and $297 million, with Adjusted EBITDA expected between $32 million and $34 million, and Adjusted Earnings per share between $0.75 and $0.80, while maintaining capital expenditures around $9 million.
XGN
Exagen Inc. reported its financial results for the third and nine months ended September 30, 2026, in a recent Form 8-K filing. The company's third-quarter revenue grew 7% to $18.4 million, while year-to-date revenue increased by 11%. Net loss decreased by 12%, and adjusted EBITDA loss improved by over 30%, with cash and cash equivalents at approximately $28.1 million. Exagen reiterated its full-year 2026 revenue guidance of $72 million to $75 million.
AMBQ
Ambiq Micro, Inc. reported third quarter 2026 financial results, showing net sales increased 110% year-over-year, driven by strong demand across customers, product families, and form factors. Gross profit more than doubled year-over-year, outpacing net sales growth. The company expects fourth quarter net sales of $43.5 million to $44.5 million, supported by accelerating demand for edge AI, with non-GAAP gross margin approximately flat to 3Q 2026, and non-GAAP operating expenses of $25.5 million to $26.5 million, reflecting investments in product development.
ABUS
Arbutus Biopharma Corporation returned $230 million to shareholders through a modified "Dutch Auction" tender offer, purchasing 46 million shares at $5.00 each, representing about 23% of its outstanding shares. The company maintains a strong financial position with $337.5 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Additionally, Arbutus expanded international patent infringement enforcement against Pfizer and BioNTech by filing new lawsuits in Japan and amending a Canadian lawsuit to include an additional LNP patent.
VREOD
Vireo Growth Inc. announced its financial results for the quarter ending September 30, 2026, and filed a registration statement on Form S-4, effective November 2, 2026, in connection with a merger with Planet 13. The company, maintaining its emerging growth status, did not opt for the extended transition period for new financial accounting standards. The merger's completion hinges on meeting specific conditions and obtaining regulatory approvals, with proxy statement/prospectus details urging careful review by stockholders.
EPRX
Eupraxia Pharmaceuticals Inc. has agreed to an open market sale of common shares with Jefferies LLC and Jefferies Securities, Inc. under a shelf registration statement, aiming to issue shares at a minimum floor price of US$1.00 per share, subject to Canadian securities laws. The British Columbia Securities Commission oversees the offering, with preliminary and final short form base shelf prospectuses filed with Canadian Qualifying Authorities.
TIMB
TIM S.A. reported a significant increase in its controlling shareholder's stake, rising from 0% to 67.760409%, with shares held increasing to 1,611,969,909. The company disclosed various securities and derivative transactions, including a compensation plan security with 0.016179% shares held by related parties. No changes were reported in the board of directors, executive management, or other key positions during the period.
HSHP
Himalaya Shipping Ltd. reported preliminary unaudited third-quarter results for 2026, with total time charter revenues of $62.2 million and average TCE earnings of $58,400 per day. The company achieved net income of $33.3 million and EBITDA of $52.7 million, while entering new time charter agreements and converting index-linked charters to fixed rates. Additionally, Himalaya increased its ownership in Peak Maritime to 60% and declared a cash dividend of $0.20 per share.
FBGL
FBS Global Limited has announced an extraordinary general meeting on November 30, 2026, to consider a name change to Lumeforta Group Limited and a significant increase in authorized share capital from US$500,000 to US$100,000,000. The capital restructuring includes 8 billion Class A Ordinary Shares, 1 billion Class B Ordinary Shares, and 2 billion Preferred Shares, all with a par value of US$0.01. Additionally, the company seeks authorization to consolidate shares into higher par value if the Class A Ordinary Shares' closing bid price remains below US$1.00 for more than eight consecutive trading days.
OWLS
OBook Holdings Inc. issued $5.75 million in Senior Secured Convertible Promissory Notes maturing on May 9, 2028, and a Class A Common Share purchase warrant expiring November 9, 2031, in a transaction with Lind Global Asset Management XV LLC. The notes and warrant, secured by a first priority security interest in the company's assets, were issued upon satisfying all closing conditions on November 9, 2026. The company also outlined a repayment structure involving cash or shares, contingent on specific conditions.
BRSYF
BrainsWay Ltd. reported a 34% revenue increase to $18.1 million in Q3 2026, with operating income surging 107% to $2.6 million. Adjusted EBITDA rose 92% to $3.9 million, and the company shipped 130 Deep TMS systems, a 44% increase year-over-year. Remaining performance obligations grew 31% to approximately $85 million, with cash and equivalents totaling $63.4 million. BrainsWay anticipates full-year results to exceed guidance, driven by expanded reimbursement coverage and increased utilization.
GIXI
Quantum X Labs has achieved a significant technological milestone in its AI-powered quantum error correction technology, demonstrating up to 20% fewer logical decoding failures in preliminary benchmarks. The results, achieved through advanced noise-model calibration, were tested using experimental data from IBM quantum processors. This milestone advances the development of more reliable and scalable quantum computing systems, marking a key step in Quantum X Labs' expanded experimental benchmarking program.
SIM
Grupo Simec, S.A.B. de C.V. agreed to acquire 100% of Acerbrag, S.A., a steel company based in Bragado, Argentina, from Votorantim, S.A., for an undisclosed amount using its own funds. The acquisition, pending regulatory approvals, aims to enhance Grupo Simec's presence in South America, increase production capacity, and generate synergies. This strategic move aligns with Grupo Simec's growth and international expansion plans, reinforcing its commitment to operational efficiency and market competitiveness.
VODPF
Vodafone Group Plc reported robust financial results for the first half of FY27, with organic service revenue increasing by 5.8% and Adjusted EBITDAaL rising 6.4% to €6.5 billion. Total revenue grew 11.4% to €21.9 billion, driven by strong service revenue and consolidations, despite adverse foreign exchange impacts. The Group upgraded its FY27 guidance, anticipating over 20% organic Adjusted Free Cash Flow growth, and highlighted improvements in customer satisfaction and operational efficiency.
MNDO
Mind CTI Ltd. is set to be acquired by Enghouse Systems Ltd. in an all-cash transaction valued at approximately $25.4 million, representing a 42% premium over the average closing price over the past 30 trading days. The merger, subject to shareholder approval and customary closing conditions, is expected to close in Q1 2027. Mind CTI reported a third-quarter 2026 financial performance with revenues of $4.4 million, an operating loss of $2.8 million, and a net loss of $2.9 million.
APXCF
Apex Critical Metals Corp. announced the extension of the Trinity Zone at its Rift Rare Earth Project in Nebraska through four additional drillholes, revealing strong rare-earth oxide (REO) mineralization. Drillhole RIFT26-026 intersected 2.52% REO over 223.3 meters, suggesting potential thickening of the mineralized zone. The company continues drilling with a single rig, targeting an inaugural mineral resource estimate by Q1/2027.
STKE
SOL Strategies Inc. reported preliminary fiscal fourth quarter 2026 results, highlighting the first full quarter of operations for Houdini Swap. The non-custodial, privacy-focused cross-chain swap aggregator generated approximately $3.4 million CAD in fees and $1.9 million CAD in EBITDA, with a 56% EBITDA margin on $1.0 million CAD in total comprehensive income from $326 million CAD in transaction volume. The company anticipates total revenue of about $4.0 million CAD for the quarter, with Houdini contributing $3.4 million CAD in swap aggregator fees.
GLMD
Eocene Ltd. has secured a European sales and distribution agreement for its CG-100 device with Hospital Line SA, granting exclusive rights to market, sell, and distribute in Greece and Cyprus. This deal is expected to lay the groundwork for further expansion into additional European markets, coinciding with Colospan's ongoing U.S. pivotal study of CG-100. The agreement includes exclusivity rights and commercial targets, with plans to launch CG-100 at the 17th Hellenic-Cypriot Surgical Conference.
IMRN
Immuron Limited engaged LifeSci Capital as its exclusive financial advisor to explore strategic initiatives, including potential mergers and acquisitions, aimed at maximizing shareholder value. The company announced the development of IMM-529, an adjunctive therapy for recurrent Clostridioides difficile infection, showing promising pre-clinical results. Immuron's technology platform supports the development of medicines for various infectious diseases, including Travelan® and ProIBS®, while maintaining Nasdaq compliance status.
SGBAF
SES S.A. reported financial results for the nine and three months ended September 30, 2026, with year-to-date revenue of €2,472 million, up 45.5% year-over-year, and adjusted EBITDA of €1,138 million, up 40.0% year-over-year. The company secured €5.8 billion in new business and contract renewals, including €3.4 billion from the IRIS 2 satellite, boosting its backlog to €10 billion. SES launched the final three O3b mPOWER satellites, enhancing network resilience and capacity, and commenced construction of a satellite manufacturing site in Luxembourg, expected to be completed by mid-2028.
CAN
Canaan Inc. reported unaudited third-quarter 2026 financial results with total revenue of US$14.5 million, near the upper end of guidance. Mining revenue decreased due to lower energized computing power and a reduced average bitcoin price, while products revenue was US$4.8 million. The company announced a US$20 million share repurchase program under a US$100 million Board authorization, highlighting its commitment to shareholder value.